Department of Medicine, Hennepin Healthcare, 701 Park Avenue, S9-309, Minneapolis, MN, 55415, USA.
Department of Medicine, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
BMC Psychiatry. 2021 Feb 17;21(1):104. doi: 10.1186/s12888-021-03113-5.
Rates of smoking among those with serious mental illness (SMI) are two to three times higher than for the general population. Smoking is rarely addressed in mental health settings. Innovative outreach and treatment strategies are needed to address these disparities. The current study is a pilot study of the feasibility and acceptability of a chronic care model of tobacco cessation treatment implemented in outpatient psychiatry clinics.
Participants were recruited from two outpatient psychiatric clinics and randomly assigned to intervention (counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment) or control (brief education and referral to the state quit line). Assessments were conducted at 8 weeks (end of initial treatment block) and 6 months (end of window for retreatment). Feasibility was assessed by enrollment rate, treatment engagement, and completion of follow-up assessments. Acceptability was assessed both quantitatively and qualitatively. Preliminary efficacy was assessed by 7-day and 30-day abstinence rates, rate of quit attempts, and cigarettes per day. Psychological health was measured to assess for changes related to treatment group or attempts to quit smoking.
Nineteen participants were randomized to intervention and 19 to control. Recruitment proved feasible, and high rates of treatment engagement (mean of 4.5 sessions completed in initial treatment block, 89.5% uptake of nicotine replacement) and retention (94.7% of follow-up assessments completed) were observed. Treatment acceptability was high. As anticipated, there were no significant differences in abstinence between groups, but results generally favored the intervention group, including bio-verified 7-day abstinence rates of 21.1% in intervention vs. 17.6% in control and self-reported 30-day abstinence rates of 16.1% in intervention vs. 5.1% in control at 8 weeks. Significantly more intervention participants made at least one quit attempt (94.7% vs 52.6%; OR = 16.20, 95% CI: 1.79-147.01). Cigarettes per day decreased significantly more in the intervention group at 8 weeks (b = - 13.19, SE = 4.88, p = .02).
It was feasible to recruit and retain SMI patients in a smoking cessation trial in the context of outpatient psychiatry. The novel chronic care model treatment was acceptable to patients and showed promise for efficacy. If efficacious, a chronic care model could be effective at reducing smoking among SMI patients.
ClinicalTrial.gov #: NCT03822416 (registered January 30th 2019).
严重精神疾病(SMI)患者的吸烟率是普通人群的两到三倍。精神健康机构很少关注吸烟问题。需要创新的外展和治疗策略来解决这些差异。目前的研究是在门诊精神病诊所实施烟草戒断治疗的慢性病管理模型的可行性和可接受性的试点研究。
参与者从两家门诊精神病诊所招募,并随机分配到干预组(8 周的咨询和尼古丁替代治疗,以及持续主动外展邀请重新参与治疗)或对照组(简短教育和转介到州戒烟热线)。评估在 8 周(初始治疗块结束时)和 6 个月(重新治疗的窗口期结束时)进行。可行性通过入组率、治疗参与度和随访评估完成情况进行评估。可接受性通过定量和定性评估进行评估。初步疗效通过 7 天和 30 天的戒烟率、戒烟尝试率和每天吸烟量进行评估。心理健康测量评估与治疗组或戒烟尝试相关的变化。
19 名参与者被随机分配到干预组,19 名参与者被随机分配到对照组。招募证明是可行的,治疗参与度高(初始治疗块完成 4.5 次治疗,89.5%接受尼古丁替代治疗),保留率高(94.7%完成随访评估)。治疗的可接受性很高。正如预期的那样,两组之间的戒烟率没有显著差异,但结果普遍有利于干预组,包括生物验证的 7 天戒烟率,干预组为 21.1%,对照组为 17.6%,自我报告的 30 天戒烟率,干预组为 16.1%,对照组为 5.1%,在 8 周时。干预组至少尝试戒烟一次的参与者明显更多(94.7%比 52.6%;OR=16.20,95%CI:1.79-147.01)。在 8 周时,干预组每天吸烟量显著减少(b=-13.19,SE=4.88,p=0.02)。
在门诊精神病学背景下,招募和保留 SMI 患者参加戒烟试验是可行的。新型慢性病管理模型治疗方法患者易于接受,且疗效有希望。如果有效,慢性病管理模式可能能有效降低 SMI 患者的吸烟率。
ClinicalTrial.gov #:NCT03822416(2019 年 1 月 30 日注册)。